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New Psychoactive Substances: towards a conceptual delim-
itation. New Psychoactive Substances (nps) are a relatively 
recent phenomenon characterized by continuous expansion 
throughout more or less the entire world in the last decade. 
They include a diversity of natural or synthetic substances that 
are not yet on official lists and whose great variety and rapid 
transformations make the nps concept itself hard to define. 
Methodologically combining qualitative methods in order to 
present a problematized systematization of national and public 
policies, and quantitative ones presenting the results of a sur-
vey applied to users of nps in Portugal, the paper contributes to 
a more precise definition of nps and their effects and to know 
about the evolution of the applicable legal framework.
keywords: New Psychoactive Substances; conceptualization; 
public policies; virtual dimension.
As Novas Substâncias Psicoativas (nsp): discussão concep-
tual. O fenómeno das Novas Substâncias Psicoativas (nsp) 
é relativamente recente e caracteriza-se por um crescimento 
contínuo na última década, um pouco por todo o mundo. 
Inclui-se aqui uma diversidade de substâncias naturais ou 
sintéticas, que não se encontram ainda enquadradas nas lista-
gens dos organismos oficiais. A sua grande variedade e rápida 
transformação configuram dificuldades de delimitação con-
ceptual. Com base numa estratégia metodológica que combina 
métodos qualitativos, na sistematização problematizada das 
políticas públicas nacionais e quantitativos, nos resultados de 
um questionário aplicado a consumidores portugueses destas 
substâncias, o artigo apresenta um contributo para a definição 
e evolução do enquadramento legal do fenómeno, das substân-
cias e dos seus efeitos.
palavras-chave: Novas Substâncias Psicoativas; discussão 
conceptual; políticas públicas; dimensão virtual.
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I N T RODU C T ION
New Psychoactive Substances (nps) are a relatively recent phenomenon char-
acterized by continuous expansion more or less all over the world in the last 
decade. They include a variety of substances that can be either natural or syn-
thetic and are not yet on the lists published by official entities, because their 
effects have not yet been tested and because they enter the market so quickly 
(emcdda, 2014). nps are thus a threat to public health (emcdda, 2011), partic-
ularly for young people, who account for most of their users (emcdda, 2015; 
2016). In general these substances include: synthetic substances created to 
mimic the effects of conventional substances and thereby circumvent the legal 
restrictions in the drugs field; substances that were developed in pharmaceu-
tical laboratories, but for some reason were either not put on the market as 
medicines, or were marketed but then withdrawn; and natural or synthetic 
substances sold with the indication that they are not for human consumption 
(examples include bath salts, plant fertilizers, incense). These psychoactive 
substances are constantly appearing, and are called “new” partly because they 
are compounds that have just been created or recreated, but also because they 
have only recently arrived on the drug market. They can be chemical innova-
tions per se, or the way in which their components are used can have recently 
changed.
This dynamic and continuous ability to transform, which characterizes 
the new psychoactive substances field, is the subject of this article, because 
it is what makes nps difficult to define and conceptually delimit, and thus in 
turn imposes constraints on the development of knowledge about the topic. 
This is especially true of the applicable legal framework, levels of prevalence, 
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and consumption patterns. We have experienced these difficulties first-hand 
as part of the project “nps: Transnational project on different user groups, user 
characteristics, extent and patterns of use, market dynamics, and best practices 
in prevention – nps:Trans”. This study was undertaken within the remit of a 
transnational and interdisciplinary eu-funded research project (Benschop et 
al., 2017) in six eu countries: Germany, Hungary, Ireland, the Netherlands, 
Poland, and Portugal. The results will enable us to offer a number of illustra-
tions of the Portuguese case throughout this article. Having said this, although 
the article focuses on the Portuguese context, our reflection on the delimitation 
of the nps concept will necessarily take account of the international framework 
in general and the current European guidelines in particular.
nps derive their particularities from the dynamics of both the drug mar-
kets and the overall consumption of substances in today’s networked societies. 
In other words, one of the characteristics of a networked society (Castells, 
2002) is linked to the way the latter not only influences the dynamics of legit-
imate sectors of the economy, but also the way it affects developments in the 
illicit market. Factors such as low-cost travel, the absence of hard borders 
between eu states, and mobility programs like Erasmus mean that it has never 
been this easy for people to move around. Never before have flows of informa-
tion and interaction been so widespread and accessible. These two groups of 
factors – personal mobility, and flows of information and interaction – have 
huge impacts on the markets, in this case the market for illicit substances in 
general and nps in particular (emcdda, 2016a).
In order to address the complex questions involving new psychoactive 
substances, we must therefore begin by giving a general overview of the public 
debate that has taken place since the issue first arose and as the relevant legal 
framework has been developed. It is thus necessary to look at the phenomenon 
from the time when it first surfaced until the present day, and to identify the 
nps universe, from the point of view of both their appearance on the market 
and what they signify for the subjects who use, produce, or simply sell them. 
This in turn implies contextualizing and understanding the substances’ signif-
icance in contemporary technological consumer societies, which are divided 
between the real and virtual planes on which individuals act, and singling out 
their importance for and impact on the various dimensions – current, politi-
cal, scientific – of the discourse linked to the subject.
M ET HOD S
We start with a brief overview of practical and ethical issues that were addressed 
related with the methodology.
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This article focuses on the Portuguese reality about nps, but it arises from 
a transnational and interdisciplinary eu-funded research project, “nps: Trans-
national project on different user groups, user characteristics, extent and pat-
terns of use, market dynamics, and best practices in prevention – nps-trans” 
(see Korf et al., 2018 and Van Hout et al., 2018 for a detailed description of 
the study methods). The project’s data-collection process included a docu-
ment-based analysis of each country’s public policies on drugs, and a survey 
among nps users.
Fieldwork occurred in 2016. Eligibility criteria among respondents for the 
survey were: recent nps use (at least once in the past 12 months); resident of 
the participating countries; and 18 years or older. The final sample of recent 
nps Portuguese users consists of 281. The data were screened/cross-checked 
for errors and analyzed using spss V.24. Analysis was conducted using ano-
nymized data and involved descriptive statistics, including frequencies and 
percentages.
In order to discuss the concept of nps in legal terms but also for its users 
in Portugal, this article is based on data collected in the Portuguese country 
report (Henriques et al., 2018) and the responses of Portuguese nps users. The 
results of this inquiry are noted in the next section and whenever necessary are 
complemented with European data.
P U BL IC P OL IC I E S A N D N P S
The nps phenomenon is essentially tied to the emergence of smartshops in 
both Portugal (Calado, 2013) and other European countries – e. g. the Czech 
Republic, Romania, and Poland (Grund et al., 2016). Between 2007 and 
2013, there were 60 physical shops located all around the country (mainland 
and islands, see Table 1) and another seven operating online (Goulão, 2013; 
 Calado, 2013). During this period, these new psychoactive substances were 
usually bought from these specialized points of sale.
Identified and publicized as legal substances during the period in which 
such smartshops existed (no longer the case), this physical and virtual trade 
network tended to make the nps that were sold in Portugal cheaper and easier 
to acquire than conventional drugs.
The ways in which these substances were initially referred to – “legal drugs”, 
“smart drugs”, “legal highs” – conveyed false ideas that their use was legal, risk-
free, had positive effects, and consequently engendered a certain permissive-
ness. The authorities started looking for a more proper designation for these 
substances that would characterize the phenomenon and reverse the mistaken 
idea of a lack of harm that was associated with the substances at the time. In 
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TABLE 1
Smartshops in Portugal, by District and Municipality (Calado, 2013)
Number of shops by District Number of shops by Municipality
Aveiro 1 Aveiro 1
Beja 1 Beja 1
Braga 2 Braga 2
Coimbra 2 Coimbra 2
Évora 2 Évora 2
Faro 6
Albufeira 2
Faro 1
Lagos 1
Portimão 2
Leiria 2
Caldas da Rainha 1
Leiria 1
Lisboa 22
Cascais 1
Lisboa 14
Sintra 3
Torres Vedras 3
V. Franca de Xira 1
Porto 5
Porto 4
Póvoa do Varzim 1
Santarém 2
Santarém 1
Entroncamento 1
Setúbal 5
Almada 2
Barreiro 1
Montijo 1
Setúbal 1
Viana do Castelo 1 Viana do Castelo 1
Vila Real 2 Vila Real 2
Viseu 2
Espinho 1
Viseu 1
Ponta Delgada 1 Ponta Delgada 1
Total 56 56
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2010 the term “New Psychoactive Substances”, a designation that incorporates 
a warning of the danger they entail (emcdda, 2011), was introduced in offi-
cial, legal, and scientific discourse. However, the term was officially adopted in 
 Portugal only in late 2012.
New Psychoactive Substances were thereafter defined as “a new narcotic 
or a new psychotropic, pure or in a preparation, which is not controlled by 
the 1971 United Nations Convention on Psychotropic Substances, but which 
may constitute a threat to public health comparable to that of the substances 
listed in those conventions” (see the sicad website).1 In accordance with the 
same logic, smartshops were also termed “points of sale of new psychoactive 
substances” (Calado, 2013).
As to the legal framework for nps, Law no. 13/2012 of 26 March 2012 
amended Executive Law n.º 15/93 of 22 January 1993 (the nineteenth time this 
Law was amended), which approved the legal regime governing the traffick-
ing in and use of narcotics and psychotropic substances. The list of controlled 
substances was lengthened with the goal of adapting the official position in 
relation to the growth of the nps phenomenon, and two nps (mephedrone and 
tapentadol) were placed on the list of illicit substances. At around the same 
time the Autonomous Madeira Region experienced a substantial increase in 
the sale and use of nps, and this led to the publication of the first regional leg-
islation with rules on protecting the population and reducing the offer of “legal 
drugs” (Regional Legislative Decree n.º 28/2012/m of 25 October 2012). All six 
shops in the Region were closed as a result.
This was an emerging phenomenon that changed considerably and 
 continually. The information available on the effects of harm linked to the 
(ab)use of these new substances was always limited and confusing, with seri-
ous implications for public health. In this respect, the Portuguese Parliament 
recommended that the government “approve rules for the protection of public 
health and take measures in this regard. [Considering the] consensus that has 
formed on the danger of new psychoactive substances that are already known, 
and thus the likelihood that new administrative offences will be created in the 
future, it was seen as indispensable to establish anti-nps health measures with 
immediate effect” (Resolution no. 5/2013 of 28 January 2013).
Shortly thereafter the government issued new legislation defining the legal 
regime governing the prevention of and protection against the advertising and 
sale of the new psychoactive substances that were already known and others 
that might appear on the market in the future (Executive Law n.º 54/2013 of 
1 http://www.sicad.pt/pt/paginas/search.aspx?k=Novas%20Subst%C3%A2ncias%20Psicoa-
tivas.
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17 April 2013). Under these new rules, it became unlawful to produce, import, 
export, advertise, distribute, sell, or possess nps or make them available. The 
new legislation also included Ministerial Order n.º 154/2013 of 17 April 2013 
(referred to in Art. 3 of the Executive Law), which approved the list of new 
psychoactive substances and made 159 new substances illegal in Portugal. 
These changes in the law immediately led to the nationwide closure of the 
smartshops, and nps are currently available only on the illicit market.
Alongside the official definition of new psychoactive substances, studies 
designed to monitor the situation were undertaken in/by various countries and 
organizations. We mention two examples in particular: “nps in Europe”, which 
focuses on nps among so-called problematic drug-users; and “nps:Trans”, 
which is seeking to underatand nps usage patterns by looking at three groups 
of users – online, recreational, and marginalized.
Another of the responses that accompanied the alterations in the law 
entailed the exchange of information, risk assessments, and nps control 
between official European organizations. In particular, emcdda, the Council 
of Europe, and the European Union Agency for Law Enforcement Coopera-
tion (europol) created a European Early-Warning System (ews) designed to 
constantly flag and investigate the appearance of new psychoactive substances 
on the market, thereby making it possible to quickly transmit and swap infor-
mation on the manufacture of, use of, and trade in nps between the Member 
States.
It is important to note that the appearance on the drug markets of new 
substances that are not yet controlled by official national and international 
mechanisms and the latter’s subsequent adaptation to the novelties is noth-
ing new. What is new is the dynamic that the market has witnessed in recent 
years in which new substances are concerned. This dynamic has resulted from 
exploitation of the growing production capacity, not only in northern Euro-
pean countries (emcdda, 2016a), but also in China and India, as well as from 
the globalization of commercial exchanges and the role of the internet (Brandt, 
King, Evans-Brown, 2014).
N P S :  E VOLU T ION ,  C AT E G OR I E S ,  A N D E F F E C T S
As mentioned above, the term “new psychoactive substances” refers to a vast 
and heterogeneous range of substances that are used for recreational and other 
purposes, and represent a growing and increasingly prevalent trend in the 
drug market. In 2009 –2014, the eu’s Early-Warning System recorded 541 new 
psychoactive substances – a figure suggesting that novelties were appearing on 
the market in terms of both offer and demand. Seizures of nps grew six fold 
 NEW PSYCHOACTIVE SUBSTANCES: TOWARDS A CONCEPTUAL DELIMITATION 811
between 2008 and 2013 (emcdda, 2015). In 2014 the ews database recorded 
about 450 nps (compared to 430 in 2013), 69 of which were reported for the 
first time (unodc, 2015).
The diversity of nps and the speed with which they appear explain why peo-
ple have found it hard to categorize, identify, and list all of the nps on the mar-
ket. Although a whole range of bodies have sought to establish nps typologies, 
even when different approaches and designations are attempted, concretely 
typifying nps is currently one of the greatest challenges, despite the efforts 
that are being made to do so. The official United Nations Office on Drugs and 
Crime2 website groups nps into nine categories based on their predominant 
characteristics: aminoindanols; ketamine and phencyclidine-type substances; 
phenethylamines; piperazines; plant derivatives; synthetic cannabinoids; syn-
thetic cathinones; tryptamines; and others. Although the European Monitor-
ing Centre for Drugs and Drug Addiction also divides nps into nine different 
groups – piperazines; benzodiazepines; arylamines; tryptamines; opioids; 
phenethylamines; synthetic cannabinoids; synthetic cathinones; and others – 
its list includes new compounds. This way of organizing these substances high-
lights the role phenethylamines, cannabinoids, and synthetic cathinones have 
been playing in the European context (emcdda, 2016b). More recently, other 
ways of (re)organizing and presenting the groups of nps that exist on the drug 
market have arisen. Examples include: synthetic cannabinoids; synthetic cathi-
nones; piperazines; phenethylamines; ketamines and phencyclidine-type sub-
stances; tryptamines; benzofurans and synthetic opiates; and others ( Zawilska, 
Andrzejczak, 2015).
In Portugal, official and regulatory definitions of nps divide them into 
seven main groups: phenethylamines and their derivatives; piperazines and 
derivatives; cathinone derivatives; synthetic cannabinoids; cocaine deriva-
tives/analogues; plants and their active principles; and others, including ket-
amine (Calado, 2013, p. 18). The case of ketamine illustrates another difficulty 
with classifying nps, which is related to the fact that the reality of use in each 
country can influence the decision whether or not to include some substances 
in an nps category. In Portugal, ketamine is officially included in the “others” 
group, but this is not so in other European countries, as we can see from the 
emcdda (2016b) classification.
Highlighting the speed with which new psychoactive substances arise, 
various authors (e. g. Zawilska, Andrzejczak, 2015) have been noting the exis-
tence of a “second generation of new substances” brought about by changes 
to the compounds used in nps that have already been identified, which are 
2 www.unodc.org
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made in order to try to circumvent legal and regulatory responses and amend-
ments as they appear. The great variety and variability of the components in 
new psychoactive substances lead to large differences in terms of biological 
activity, pharmacological parameters, and effects on subjects, all of which have 
major implications for their definition, classification, and identification, both 
by agents involved at the political, social, chemical, medical, and other levels, 
and by users themselves.
These difficulties are compounded by another, which is linked to the dif-
ferent denominations used to identify new psychoactive substances. The fact 
is that nps are referred to by a wide range of “monikers” (street and brand 
names) and the scientific names of compounds or chemical formulae. For 
example, there are products whose composition includes α-pvp (α-pyrrolid-
inovalerophenone) with street names like “Ocean Breath”, “Fire Ball”, “Total 
speed”, “Sensation”, “Speedway”, “Guarana Coco jumbo”, “Energy 3 (nrg-3)”, 
and “Sextasy” (emcdda, 2015).
Given these difficulties with classifying and grouping these new sub-
stances, we propose a system that is based on the type of substance and its 
primary effects on the central nervous system, and is capable of encompass-
ing the various categories of nps: synthetic cannabinoids; synthetic stimulants; 
hallucinogens/psychedelics; and opiate-type synthetics.
Like many other drugs, the origins of synthetic cannabinoids lie in exper-
imental laboratory work, in this case in the middle of the first decade of the 
21st century. The market for those substances then began to develop quickly 
and clandestinely, culminating in large numbers of products coming onto the 
market as cannabis alternatives (Castaneto et al., 2014). Over the course of 
2014, the eu ews identified 134 nps of a synthetic cannabinoid type, which 
makes them the largest group of nps available on the market. Current street 
names include “Spice” in Europe, “k2” in the us, “Kronik” in Australia and 
New  Zealand, and “Fidel-Mix” in Portugal (sicad, 2013, 2014; Silva, 2012; 
Zawilska, Wojcieszak, 2014).
Synthetic cannabinoids are sold as herbal mixtures for smoking, and they 
are presented in packaging decorated with a variety of drawings and other 
images. The majority are produced in China and combine a mixture of herbs 
(e. g. melissa, mint, thymus, damiana) dissolved or pulverized in/with acetone, 
ethanol, or methanol. After drying, this compound is generally presented in 
the form of a powder (emcdda, 2015a). There is limited available informa-
tion on the volume of synthetic cannabinoids that is consumed (emcdda, 
2016b). In Portugal their use was more prevalent at the time of the smartshops, 
between 2007 and 2013 (sicad, 2013; Silva, 2012), but it now appears to rep-
resent a smaller proportion of the overall market. In the “nps:Trans” project 
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in Portugal, around 20% of the respondents to the questionnaire-based survey 
(not representative of the general population) said that they had used synthetic 
cannabinoids in the last year.
The relative importance of these substances can be seen in the fact that 
by December 2015, the eu ews had notified emcdda of the existence of 160 
synthetic cannabinoids belonging to 14 chemical families (emcdda, 2016b).3 
They are also important because emcdda has recorded a range of adverse 
occurrences with serious effects for human health as a result of the use of these 
substances (ibid). However, current knowledge about the pharmacological and 
toxicological effects of some synthetic cannabinoids is still limited – a limita-
tion that is accentuated by the speed with which new variations and evolutions 
in the application of the substances appear on the market. One example is the 
inclusion of synthetic cannabinoids in the liquid used in electronic cigarettes 
and associated with the increasingly popular vaping phenomenon (ibid).
Turning to synthetic stimulants, cathinones are another large group of nps 
that are available on the market. Synthetic cathinones and their derivatives 
comprise compounds that are chemically related to cathinone, which in the 
last decade was a class of substances that hit the market in a big way, namely in 
the form of recreational drugs and alternatives to psychostimulant substances 
that were already controlled (e. g. amphetamines, methamphetamines, and 
mdma). Essentially presented as “plant fertilizers”, “bath salts”, or “research 
chemicals”, these substances currently constitute the second-largest group of 
nps available on the European market. Between 2005 and 2014 the eu ews 
mechanism identified more than 80 cathinone-derivatives (emcdda, 2015a), 
with the most popular seeming to be mephedrone, methylone, and mdpv 
(3,4-dimethoxypyrovalerone).
Although many substances have been deliberately created in order to avoid 
drug legislation, others result from substances that were originally developed 
by the pharmaceutical industry and for one reason or another were either not 
put on the market, or were withdrawn from it. Many of the new substances 
that have recently entered the market are the result of the rediscovery of these 
pharmacological compounds and their commercial potential when offered on 
the drug market.
This picture includes synthetic cathinones that are not really recent. 
Mephedrone, for example, was first synthesized in 1929, pmma in 1938, and 
3 The European Monitoring Centre for Drugs and Drug Addiction (2016b) has published 
an interactive model for simulating the chemical composition of synthetic cannabinoids, which 
clearly displays their complexity – Interactive: demystifying the chemistry in http://www.emcdda.
europa.eu/topics/pods/synthetic-cannabinoids#panel2.
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mdpv in 1969 (unodc, 2013). However, they became a major market presence 
only in the last decade. Mephedrone and its derivatives thus ended up being 
placed on the 1971 Drugs list on 16 April 2010, and on the Portuguese equiv-
alent in 2012, with the implementation of Law n.º 13/2012 of 26 March 2012, 
which added mephedrone and tapentadol to the annex of tables of psychoac-
tive substances that are illegal in this country. Despite this, the substances’ high 
level of popularity and the ease and speed with which they can be produced 
have meant that the new laws have not sufficed to keep them off the market, 
with the appearance of new compounds that are analogous to mephedrone, 
such as: 4-mec; 4-meppfvp; 4-mppp; and pvp, which is analogous to mdpv 
(Zawilska, Andrzejczak, 2015).
Other nps with stimulant psychoactive effects include the compounds 5- 
and 6-apb, which appeared on the recreational drug market in 2010-2011 and 
are analogous (compounds with a similar, albeit slightly modified, molecular 
structure) to amphetamines, such as benzofuran. We also find aminorex ana-
logs, such as 4,4’- dmar and mdmar. This compound was originally synthe-
sized in pharmaceutical laboratories in the mid-1960s and was registered in 
Europe as an appetite suppressor in 1965, but was withdrawn shortly there-
after due to its collateral effects (above all, pulmonary hypertension). Amin-
orex then reappeared on the recreational drug market a few years later, and 
emcdda identified it in 2012 and included it on the nps list in 2014 (emcdda, 
2014). Available as powders or pills, many of these substances surfaced with 
names that are very similar to those of other, more conventional recreational 
designer drugs: “Playboy”, “Mitsubishi”, “Transformers”, and so on. However, 
given their characteristics, they can appear in the form of ecstasy tablets. 
Their most common forms of use are oral ingestion and inhalation (emcdda, 
2014a).
When it comes to hallucinogenic nps, of particular note have been the 
appearance of compounds like the second generation of -2c phenethylamines 
(nbome), methoxetamine (mxe), diphenidine, and 2-methoxydiphenidine. The 
structural base underlying phenethylamine is found in various nps – namely 
catecholamines and 2c-type drugs. Since 2c-b substances have become legally 
controlled, various compounds have been reinvented, synthesized, and placed 
on the market. This is the case of the phenethylamine substitutes (nbome) 
25b-nbome (2c-b-nbome), 25c-nbome (2c-c-nbome), and 25i-nbome (2c-i-
nbome). Current street names include “n-Bomb”, “Smile”, and “cimbi-5”. 
Because they mimic the effects of conventional substances, some of them have 
been marketed as lsd substitutes – the case of the 25c-nbome and 25i-nbome 
compounds (emcdda, 2015; Zawilska, Andrzejczak, 2015). nbome-type sub-
stances can be found on the market in the form of pills, capsules, powder, 
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liquid, spray, or packaged in small individual doses (Zawilska, Andrzejczak, 
2015).
Within this group it is also important to mention Salvia Divinorum, whose 
active agent, salvinorin A, makes it a short-lived hallucinogen (Deluca et al., 
2009; Calado, 2013). This substance can be found for sale as extracts from 
Salvia Divinorum leaves fortified with salvinorin A solution.4 Although Salvia 
Divinorum is permitted in some countries, it was made illegal in Portugal on 
17 April 2013 (Ministerial Order 154/20135). As such, while it is not neces-
sarily a new substance, the way in which it reappeared and has become part of 
new patterns of recreational use makes it a clear example of a new psychoactive 
substance.
Finally, we have the synthetic opiate-type substances, which include the 
compounds ah-7921 and mt-45. The former was synthesized and patented 
in 1976 as an opiate painkiller; the latter was also developed in the 1970s, by 
a Japanese pharmaceutical company. Other substances have appeared under 
the name “doxylam”, and are made from the ah-7921 compound (emcdda, 
2014b).
Our proposed generic classification is not necessarily as exhaustive as it 
might be if it were driven by purely chemical and pharmacological criteria. But 
it does have the benefit of simultaneously offering a general organization and 
a response to the pharmacological diversity, the complexity of the compounds, 
and the potential lack of knowledge associated with their rapid evolution and 
transformation. A situation that is further accentuated by the large number of 
substances and their generally widespread availability.
N P S ,  T H E I N T E R N ET,  A N D T H E V I RT UA L DI M E N SION
OF T H E I L L IC I T DRU G M A R K ET
In the last decade the issue of drugs has changed in various ways, challenging 
researchers to stay abreast. Many of these changes have been driven by tech-
nological innovation, with impacts not only in terms of new forms of commu-
nication and interaction and the ways in which substances are sold, but also 
on the theoretical and empirical approaches adopted in recent investigation 
in this field. The focus on the role the internet is playing in the offer of and 
4 The level of concentration of the bath determines the intensity of the effects, and can range 
from 5 times more to 60 times more.
5 “(145) Salvia Divinorum (and the respective constituent psychoactive elements salvinorin 
a and salvinorin b)”, Plants and respective active constituent elements, Annex to Ministerial 
Order 154/2013 of 17 April 2013.
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demand for illicit drugs in general and new psychoactive substances in par-
ticular has been one of the main examples of this, but also one of the primary 
challenges when it comes to the more traditional dynamics, which are the ones 
that have been most often studied in recent years (new substances, trafficking 
routes, forms of acquisition, criminal networks) (Pires, Borges, Valente, 2015; 
emcdda, 2016).
The internet is democratizing access to information, ensuring that it 
remains accessible to all, while also providing new opportunities. In this digital 
scenario, substance users, dealers, researchers, and others with an interest in 
the subject of drugs all use technology and take advantage of easy access to the 
internet and mobile devices. The development of new means of information 
and communication has led to the emergence of discussion forums, webpages, 
applications, and other instruments in which the topic of drugs is discussed 
and substances are either promoted or argued against, and sometimes sold.
The problematic aspects of drugs are essentially linked to illicit markets, 
even in scenarios like the Portuguese one, in which use is not criminalized. 
Within this context the option for the parties to remain anonymous and avoid 
personal contact is both a self-protective strategy and an advantage within the 
dynamic of these online markets.
A number of studies have focused on the question of the online market 
for new psychoactive substances, based on the i-trend – Internet Tools for 
Research in Europe on New Drugs software, which monitors online nps shops. 
“i-trend” has highlighted the virtual dimension of the drug phenomenon, 
and especially its capacity to adapt and respond to each country’s or reality’s 
markets, cultures, and usage habits (emcdda, 2016a). Other studies point to 
the advantages of this virtual dimension of the markets in terms of reducing 
interpersonal conflicts, inasmuch as interactions take place only online and on 
the basis of anonymity, and substances are potentially less likely to be adulter-
ated because there tends to be a direct relationship between users and produc-
ers (Pires, Borges, Valente, 2015).
The changes in national, European, and international legislation seem to 
have contributed to the move from physical markets, such as smartshops, to 
the virtual market, with the latter in both its surface form (more accessible) 
and deep-web form (more restricted, can be seen as the web’s “underworld” – 
i. e. the part of the internet that cannot be accessed via conventional servers, 
but only from another particular type of website, using “hidden servers” and 
specific skills). nps appear above all on the deep web, where they are available 
from the darknet or “cryptomarkets” (part of the deep web that is accessible 
only via specific browsers that protect users and conceal search and use his-
tories; examples include Tor, which is short for “The Onion Router”, a search 
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engine that hides a computer’s ip address – the primary way of identifying 
a subject who uses the internet – and thereby protects their privacy) (Pires, 
Borges, Valente, 2015; emcdda, 2016). The “dark” benefit is the fact that it is 
currently possible to conduct any type of transaction in this way, and that the 
location and real identity of the parties are irrelevant. Similarly, it is possible to 
share experiences of using a given substance in real time, thereby promoting it. 
There are no legal or other constraints in these commercial spaces (Aldridge, 
Décary-Hétu, 2014), identities are protected, financial transactions employ 
bitcoins or “litecoins”, and communications are encrypted/encoded.
One of the first cryptomarkets to appear (2011) was the “Silk Road” – a 
sophisticated and innovative marketplace in which it was possible to acquire 
all kinds of substances at a wide range of prices. One of its innovative charac-
teristics was that it required a whole assessment process designed to ensure 
customer satisfaction by means of ratings of/by producers, sellers, and end 
users. The goal of this feature of the marketplace was to establish relationships 
of trust between users and promote demonstrations of quality and reliability 
to potential customers (Aldridge, Décary-Hétu, 2014). The Silk Road was shut 
down in October 2013, but other platforms, such as Black Market Reloaded, 
The Armory, Evolution, and Agora have since appeared. In accordance with 
their mercantilist vocation, these types of platform have gradually improved 
the ways in which they monitor all the processes inherent in transactions, and 
are considered “resilient” markets – i. e. ones with the ability to adapt to new 
adversities and obstacles (emcdda, 2016a).
In short, cryptomarkets are a second generation of parallel networks that 
differ from the first ones by their main characteristics (Aldridge, Décary-Hétu, 
2014; Van Hout, Bingham, 2013):
1) Payments are made using virtual currency (e. g. bitcoins). 
2) Subjects are required to accept an anonymous protocol (e. g. Tor, or the 
Invisible Internet Project – i2p), thereby ensuring the absence of iden-
tifying elements and eliminating probabilities that the hidden servers 
will be traced and identified.
3) Incentives to keep transactions confidential, in such a way as to avoid 
the capture and sharing of information about illicit dynamics.
4) Use of an online assessment system, whereby the various parties can 
give their feedback about a given transaction, product, or delivery, the-
reby differentiating and highlighting certain quality criteria.
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Recent studies suggest that nps may be being sold as traditional substances 
(e. g. nbome as lsd), and that this increases the number of unintentional and/or 
unaware transactions, above all among certain groups, such as recreational and 
problematic drug users (Brandt, King, Evans-Brown, 2014; Grund et al., 2016).
In Portugal, both media pieces and scientific studies have shown the exis-
tence of a trend toward nps use among minors (Silva, 2012; European Commis-
sion, 2011, 2014). However, there are still difficulties in producing knowledge 
in the nps field, on the one hand due to its dynamic and rapid evolution, as 
described in this article, and on the other to a certain lack of knowledge about 
nps displayed by psychoactive-substance users themselves.
These characteristics – the low level of knowledge, and the existence of 
some unintentional and unaware use – were also identified during the field-
work conducted as part of the “nps:Trans” study. These difficulties underscore 
the need to deepen both the knowledge and the discussion about data on the 
prevalence of nps use, their effects, and representations about them, as gath-
ered from users themselves.
The results of the questionnaire-based survey applied as part of the proj-
ect between June and October 2016 indicate that 281 Portuguese persons (the 
respondents), the majority of whom were male and between 18 and 46 years of 
age, had already used at least one nps – see Table 2.
This table presents the data collected on nps use in a Portuguese context 
and developed within the framework of the broader European study. The 
TABLE 2
NPS used
 
NPS
Frequency of use %
In the last 12 months,
but not in the last 30 days
In the last 30 days
Mixture of herbs 7.1 4.6
Synthetic cannabinoids 8.2 11.7
Branded stimulants 6.8 3.9
Stimulants/Empathogens/
Nootropics
11.7 4.6
Psychedelics 35.6 28.8
Dissociatives 10.0 3.6
Others 14.2 19.2
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 prevalence of hallucinogenic and stimulant-type substances confirms the 
results of other, earlier studies carried out in the same context, namely that 
of Pires, Borges and Valente (2015). However, all our fieldwork highlighted 
the fact that these are emerging substances with different origins and natures, 
and that there is thus little available information about their bioactive prop-
erties, including among users. This means that it is not possible to know the 
composition of the substances that are used, except from samples taken by the 
country’s drug-testing service. In this respect, it is important to emphasize that 
users were asked whether they knew exactly what substance they were taking 
(e. g. what mixture of herbs, or what synthetic cannabinoid) and if they knew 
what the active agent was. The most common response for all the substances 
was “no”. Having said this, and despite these difficulties in terms of recognition 
or an apparent lack of knowledge, 21.3% of respondents said their preferred 
substance was 2cb (a hallucinogen).
These data once again confirm our above arguments on how difficult 
it is to achieve a conceptual definition of nps. However, they also reinforce 
the idea that to the extent that many of these substances mimic the effects of 
conventional ones, they may be being sold and used as though they were the 
latter without their users really being aware of it. The drug-testing services 
around Europe, including in Portugal, that are present in recreational con-
texts – above all, festivals – seek precisely to collect and provide information 
on the substances in circulation and their degree of purity. Users are invited to 
submit their substances for analysis, and are given the results along with rele-
vant information about reducing risks and minimizing harm (Giné, Espinosa, 
 Vilamala, 2014; Brunt et al., 2017).
Although almost all of the studies that have been conducted to date sug-
gest a relatively low level of prevalence of nps use in recreational contexts, the 
tendency for the number of new substances to rise is likely to continue. This 
rising trend is having serious implications in terms of both the risks associated 
with use and the number of regular users, and is reflected in difficulties in 
finding responses that are appropriate to the problems (Brandt, King, Evans- 
-Brown, 2014) (for example, at the level of the substitutional pharmacotherapy 
employed in cases of nicotine or heroin addiction, and of other therapeutic 
methods applied in cases of addiction to cocaine or amphetamine-type psycho-
stimulants). Another of the related risks concerns certain forms of use, such as 
substance injection. We also know that there are nps that are being consumed 
as though they were conventional substances, in situations of false labelling 
(when the substance does not correspond to what it is supposed to be, or to 
what is written on the packaging) and unintentional nps users (Brandt, King, 
Evans-Brown, 2014; emcdda, 2015). This is both a warning and an  additional 
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challenge for the specialist staff who work in the risk-reduction field. It seems 
to us that one cannot dissociate the recent increase in the number of inject-
ed-substance users in Portugal from this context.6
Although, as we have already said, drug-users can be induced to consume 
nps without their knowledge, and as such the level of prevalence of use may be 
being underestimated, the reasons given for using nps do not present substan-
tial differences compared to those given by users of conventional substances. 
In the “nps:Trans” project, the reasons respondents gave for their uses are 
shown in Table 3.
Among this set of reasons, the ones that stand out are those most directly 
linked to hedonism, the search for self-knowledge, and a certain distancing 
from reality. An analysis of the phenomenon of new psychoactive substances 
in a globalized context should consider a range of mechanisms and forces that 
influence it. Some authors, such as Brandt, King, and Evans-Brown (2014) for 
example, argue that the use of psychoactive substances at present is likely to be 
one of the manifestations of the increasing medicalization of society that runs 
right through the debate on and understanding of the concepts of health, per-
formance, fun, and consumption. The nps phenomenon clearly goes beyond 
the designer drugs that marked the last decade of the 20th and the first few 
years of the 21st centuries, and is now taking on new shapes against the back-
drop of an open market, with “legal highs” and “research chemicals”.
Within the context of today’s consumer societies, pleasure is taking on a 
market value, and as such, the discussion about nps needs to incorporate two 
complementary dimensions. One concerns the improper use of prescription 
medicines as an emerging question of global import (Van Hout, 2014). The 
other involves dietary supplements, such as products that are widely available 
from e-commerce websites, online “pharmacy-food” shops,7 and fitness-re-
lated shops. In most cases they are presented as “natural”, in order to exploit 
the generalized belief that these are healthy, safe consumer choices. The avail-
ability of these products warrants particular attention, because almost none 
of their producers and sellers are covered by substance monitoring systems 
(Griffiths, Evans-Brown, Sedefov, 2013).
6 In this respect, see e. g. the news item published in Visão magazine on 12 January 2017, 
available in Portuguese at http://visao.sapo.pt/actualidade/sociedade/2017-01-29-Os-novos 
-casais-ventosos.
7 The equivalent Portuguese term alicamentos (a junction of the words for food – alimentos – 
and medicines – medicamentos) refers to products that are presented as medicines (Henriques, 
2007).
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TABLE 3
Reasons for NPS use
Motivations *
Frequency of use %
The majority
of times
Almost always/
/Always
To forget my worries 3.2 1.8
To cheer me up when I’m in a bad mood 4.6 2.5
Alleged legality 1.8 4
To forget bad problems 3.2 2.8
Because I like the feeling 20.6 50.2
Poor quality of other drugs 2.8 1.4
Because they give me a pleasant sensation 20.6 46.6
Because they help me when I’m depressed or nervous 3.6 5.0
To get to know myself better 10.0 14.6
Because it’s fun 18.5 45.9
Because they help me enjoy a party 21.0 29.9
To get high 7.5 22.8
To be sociable 5.0 4.3
Out of habit 3.2 2.5
Because of the price 1.4 1.8
So that people like me 0.7 0.4
Because they make social events more fun 15.7 16.4
Different or new experiences 14.2 32.0
Because they improve parties or celebrations 14.2 19.6
Because they’re undetectable 1.4 1.4
Because I feel more self-confident and sure of myself 5.0 3.6
To be accepted in the group I like 1.8 0.4
To expand my perception 16.4 26.7
Conventional drugs are had to get 2.8 2.5
To not feel excluded 0.4 0.4
Because they help me be more creative and original 8.5 10.0
Out of boredom 1.8 1.1
To understand things in a different way 10.0 18.9
To be more open to experiences 12.5 25.3
To have fun 15.3 47.3
To celebrate a special occasion with friends 14.9 20.6
* It is important to note that these motivations are broken down here in order to permit international compa-
risons within the broader framework of the “NPS:Trans” European study.
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F I NA L R E M A R K S
The goal of the present article was to contribute to the discussion on a concep-
tual delimitation of new psychoactive substances, whose opaque nature has 
made advances more difficult on various levels: knowledge, policies, and inter-
vention. To this end we began by situating the nps phenomenon in terms of 
the relevant public policies; and then presented a proposed nps classification 
based on the type of substance and its effects on the central nervous system. 
Albeit a general one, this way of organizing these substances is designed to 
respond to their pharmacological diversity and the complexity of their com-
ponents.
In the case of nps, the virtual dimension of the drug market seems to take 
on a particular and poorly known dynamic. This dimension is relevant from 
the point of view of both the offer of and the demand for nps. With regard 
to the former, it is important to understand the routes, the circuits, the flows 
of information that are generated, the specific forms of transaction, and the 
(re)definition of the roles of the producer vis-à-vis the seller. When it comes 
to the latter, it is important to know the profiles of users, the patterns and 
prevalences of use, and the characteristics of the interactions and interaction 
networks that are established.
The data collected in relation to the Portuguese reality and within the 
overall framework of the “nps:Trans” project have enabled us to illustrate the 
discussion with empirical information. In particular, the data on the nps that 
are in use and the reasons for that use, which were gathered from users in 
recreational contexts and virtual environments, result in knowledge that can 
potentially impact the definition of strategies for both preventing and reducing 
risks and minimizing harm.
In conclusion, there is an indisputable need to increase knowledge about 
the nature and usage patterns of nps and the potential risk associated with 
the substances, so as to then be able to identify potential areas of intervention 
and focal points for the development of preventive strategies (Giovanni et al., 
2015). In this respect, we have pointed to a number of lines of action that 
deserve emphasis and are capable of complementing the updates to the sub-
stances’ legal status as they gradually come about (Corazza et al., 2012; 2013). 
One entails monitoring online activities, which is essential if one is to map 
the dissemination of nps. Another involves incorporating technological tools 
into specific prevention programs. Finally, the involvement of international 
and multidisciplinary partnership networks is especially important in light of 
the challenges created by the nps problem, namely in terms of how novel the 
substances are and how fast they are expanding.
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In summary, while all these particularities of nps are common to, and key 
factors in, their appearance in certain markets, and although the development 
of information and communication technologies is a reality on a global scale, 
it is nevertheless necessary to conduct a whole exercise designed to define and 
conceptualize nps, because usage cultures and habits appear to vary from one 
country, one context, and one user group to another.
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